Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.33 |
| ▸ | VEGFA | P15692 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511368 | 0.87 | KCNH2 (0.45) | KCNH2KMT2AMAPTCYP3A4SLC22A12 | |
| SCHEMBL2515815 | 0.82 | KCNH2 (0.44) | KCNH2KMT2AMAPTCYP3A4MEN1 | |
| SCHEMBL2512033 | 0.81 | KCNH2 (0.47) | KCNH2KMT2AMAPTCYP3A4SLC22A12 | |
| SCHEMBL2512723 | 0.81 | KCNH2 (0.43) | KCNH2KMT2AMAPTCYP3A4SLC22A12 | |
| SCHEMBL2513710 | 0.80 | MAPT (0.31) | KMT2AMAPT | |
| SCHEMBL2512769 | 0.80 | KCNH2 (0.42) | KCNH2KMT2AMAPTCYP3A4SLC22A12 | |
| SCHEMBL2509884 | 0.77 | KCNH2 (0.40) | KCNH2KMT2ACYP3A4MEN1TTR | |
| SCHEMBL2509224 | 0.76 | KCNH2 (0.44) | KCNH2KMT2AMAPTCYP3A4SLC22A12 | |
| SCHEMBL1344317 | 0.76 | KCNH2 (0.47) | KCNH2CYP3A4SLC22A12EPAS1VEGFA | |
| SCHEMBL2548859 | 0.76 | KCNH2 (0.43) | KCNH2KMT2AMAPTCYP3A4SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2924034-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | MERCK CANADA INC (CA) | 2016-11-02 | — | — | EP | disclosed |
| EP-2924034-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | MERCK CANADA INC (CA) | 2016-11-02 | — | — | EP | disclosed |
| EP-2924034-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | Merck Canada Inc. (CA) | 2015-09-30 | — | — | EP | disclosed |
| EP-2924034-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | Merck Canada Inc. (CA) | 2015-09-30 | — | — | EP | disclosed |
| EP-2552902-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC (CA) | 2015-03-11 | — | — | EP | disclosed |
| EP-2552902-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC (CA) | 2015-03-11 | — | — | EP | disclosed |
| US-20130296382-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-20130296382-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-20130296382-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-8486975-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK CANADA INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-8486975-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK CANADA INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-8486975-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK CANADA INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| EP-2552902-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Canada Inc. (CA) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011120133-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011120133-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245296-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-06 | — | — | US | disclosed |
| US-20110245296-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-06 | — | — | US | disclosed |
| US-20110245296-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296382-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, REV1, POLR2E | KCNH2 3760/4885KMT2A 1259/4885MAPT 1311/4885 |
| US-20110245296-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, REV1, POLR2E | KCNH2 3760/4885KMT2A 1259/4885MAPT 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.